

Hybrigenics' patent estate of inhibitors of ubiquitin-specific proteases is expanding

- **Hybrigenics' patent on its fourth chemical family of inhibitors of ubiquitin-specific proteases (USP) is granted in Europe**
- **Hybrigenics' patent on its first chemical family of USP inhibitors gets three more protection years in the USA**
- **HBX 41,108, one of the first Hybrigenics' patented USP inhibitors, is now licensed to the Bio-Techne group as a reference pharmacological research tool**

Paris, 04 September 2014 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments of proliferative diseases, today announces the grant by European Patent Office of Hybrigenics' fourth patent on inhibitors of ubiquitin-specific proteases (USP). Filed early in 2011, this patent has been successfully examined according to an accelerated procedure and will give the patented compounds protection until 2031 in Europe.

In addition, Hybrigenics has recently received a three-year extension to the term of its first patent on USP inhibitors in the United States: until mid-2029 instead of mid-2026 in Europe and in the rest of the world. This first family includes HBX 41,108, Hybrigenics' first lead compound (see Hybrigenics' press release of August 24, 2009). HBX 41,108 is now a reference USP inhibitor commercialized by the Bio-Techne group of companies (Tocris, Boston Biochem, R&D Systems) and distributed by Fischer Scientific, under Hybrigenics' worldwide license. It is sold as a pharmacological tool to scientific laboratories only for experimental research use *in vitro* and *in vivo*, but not for tests in humans.

In total, Hybrigenics' intellectual property on USP inhibitors amounts to 56 granted patents protecting four chemical families and spread over more than thirty countries. A fifth chemical family and a total 38 patent applications are still pending examination worldwide.

"Hybrigenics' pioneering research on USP inhibitors has been successfully transformed into definitive valuable intellectual property assets for the next 12 to 17 years," said Remi Delansorne, Hybrigenics' CEO.

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases and providing cutting-edge proteomic and genomic scientific services.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol has also been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.

Hybrigenics Services (www.hybrigenics-services.com) is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform.

Helixio (www.helixio.com), Hybrigenics' genomic branch, provides state-of-the-art services specialized in DNA chips, DNA or RNA target enrichment and next generation sequencing.

Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.

HYBRIGENICS

Press Release

HYBRIGENICS is listed on the Alternext market of Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics

Rémi Delansorne

CEO

Tel.: +33 (0)1 58 10 38 00

investors@hybrigenics.com

NewCap

Financial communication

Julien Perez / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

hybrigenics@newcap.fr